Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.
AcelRx Pharmaceuticals saw an increase in earnings per share from -1.0 in Q4 to $-0.75 now. Organon's earnings per share for Q1 sits at $1.11, whereas in Q4, they were at 0.81. Its most recent dividend yield is at 4.62%, which has increased by 0.79% from 3.83% in the previous quarter.
Histogen has reported Q1 earnings per share at $-0.81, which has decreased by 32.79% compared to Q4, which was -0.61. This quarter, Allarity Therapeutics experienced an increase in earnings per share, which was $-322.0 in Q4 and is now $-177.2. Most recently, Helius Medical Tech reported earnings per share at $-0.09, whereas in Q4 earnings per share sat at $-0.17.
These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.